Kybora

KYBORA is pleased to announce the licensing of Accure Therapeutics ACT-01 to Oculis.

3 3 月, 2022
 Comments are off for this post.
Global Licensing
KYBORA is pleased to announce the licensing of Accure Therapeutics ACT-01 to Oculis.

KYBORA is pleased to announce the global licensing of ACT-01 from Accure Therapeutics to Oculis. This transaction further demonstrates KYBORA’s expertise in delivering global biopharma licensing deals and in the ophtalmology space

Read more

TYPE & ENTER: